<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161432">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01885195</url>
  </required_header>
  <id_info>
    <org_study_id>CMEK162AUS11</org_study_id>
    <nct_id>NCT01885195</nct_id>
  </id_info>
  <brief_title>MEK162 for Patients With RAS/RAF/MEK Activated Tumors</brief_title>
  <acronym>SIGNATURE</acronym>
  <official_title>Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this signal seeking study is to determine whether treatment with MEK162
      demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic
      malignancies to warrant further study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, open label study to determine the efficacy and safety of treatment with
      MEK162 in patients with a diagnosis of select solid tumors or hematological malignancies
      that have been pre-identified (prior to study consent) to have activations of the
      RAS/RAF/MEK pathway and whose disease has progressed on or after standard treatment.

      Genomic profiling is becoming more accessible to patients and their physicians. This is a
      signal-seeking study to match patients with mutations in RAF, RAS, NF1 or MEK to the
      ATP-noncompetitive MEK 1/2 inhibitor, MEK162. Pre-identification of these mutations or
      activations in the pathway will be performed locally at a CLIA certified laboratory prior to
      screening for participation on the trial.

      Once the patient has been identified, treating physicians who are qualified investigators
      may contact Novartis to consider enrollment in this study. For the purpose of this study,
      genomic profiling is not considered part of screening. Informed consent must be signed
      before any screening activities take place. Once eligibility (screening criteria met) has
      been confirmed by Novartis, the patient will initiate therapy with single agent MEK162. The
      patient may not receive any additional anti-cancer therapy during treatment with MEK162.

      Patients will continue to receive study treatment until disease progression (assessed by
      RECIST 1.1 or appropriate hematologic response criteria), unacceptable toxicity, death or
      discontinuation from study treatment for any other reason (e.g., withdrawal of consent,
      start of a new anti-neoplastic therapy or at the discretion of the investigator), otherwise
      known as End of Treatment. All patients who discontinue from study treatment due to disease
      progression must have their progression clearly documented.

      Disease assessment (per RECIST 1.1 or appropriate hematological response criteria) will be
      performed every 8 weeks (±4 days) after first dose of study drug (Day 1 of every odd cycle),
      until disease progression or end of treatment, whichever occurs first. The frequency of
      disease assessment may be reduced to every 12 weeks for patients who have at least 4
      post-baseline disease assessments and are clinically stable (except AML and MM patients).
      Scans will be assessed locally by the investigator. After discontinuation of treatment,
      patients, regardless of reason for treatment discontinuation, will be followed for safety
      for 30 days after the last dose.

      All patients will be followed for survival status every 3 months for 2 years after the last
      patient has enrolled in the study regardless of treatment discontinuation reason (except if
      consent is withdrawn or patient is lost to follow-up.)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical benefit rate associated with MEK162 treatment</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical benefit rate for patients with solid tumors will be assessed using RECIST 1.1 and will include responses of CR or PR or SD. For hematologic tumors other appropriate hematological response criteria will apply</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response (OR) or Partial Response (PR) or greater</measure>
    <time_frame>baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall Response (OR) of Partial Response (PR) or greater based on local investigator assessment. For patients with solid tumors, the assessment criteria will be RECIST 1.1 and will include responses of CR and/or PR. For hematologic tumors other appropriate hematological response criteria will apply.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>every 8 weeks until death, assessed up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression free survival (PFS) is defined as the time from the date of first dose to the date of first documented disease progression or relapse or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>every 8 weeks until death, assessed up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival (OS) is defined as the time from the date of first dose to the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The duration of response (PR or greater) applies only to patients whose best response was PR or greater. It is defined as the Ttime from the first documented response to the date first documented disease progression or relapse or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of Safety and Tolerability</measure>
    <time_frame>baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety and tolerability will be will be based on the frequency of adverse events and on the number of laboratory values that fall outside of pre-determined ranges. Other safety data (e.g., electrocardiogram, vital signs) will be considered as appropriate.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Solid Tumor and Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>MEK162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEK162</intervention_name>
    <description>MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.</description>
    <arm_group_label>MEK162</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has a confirmed diagnosis of a select solid tumor (except for primary
             diagnosis of pancreatic cancer, biliary cancer, colorectal cancer, low grade serous
             ovarian cancer, melanoma) or hematologic malignancy (except for primary diagnosis of
             chronic myelomonocytic leukemia).

          -  Patients must be pre-identified as having a tumor with a mutation in RAF, RAS, NF1 or
             MEK at a CLIA certified laboratory

          -  Patient must have received at least one prior treatment for recurrent, metastatic and
             /or locally advanced disease and for whom no standard therapy options are anticipated
             to result in a durable remission.

          -  Patient must have progressive and measurable disease as per RECIST 1.1. or other
             appropriate hematological guidelines.

          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

        Exclusion Criteria:

          -  Patient has received prior treatment with MEK162.

          -  Patients with primary CNS tumor or CNS tumor involvement

          -  History of retinal degenerative disease

          -  History or current evidence of central serous retinopathy (CSR) or retinal vein
             occlusion (RVO)

          -  Any ophthalmopathy visible at screening that would be considered a risk factor for
             CSR or RVO by the ophthalmologist

          -  Patients who have neuromuscular disorders that are associated with elevated CK
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-855-744-6727</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alaska Oncology and Hematology AOH (2)</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>907-264-1579</phone>
    </contact>
    <investigator>
      <last_name>Max Rabinowitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates AZ Oncology Assoc.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>602-274-5141</phone>
    </contact>
    <investigator>
      <last_name>Michael Roberts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group Highlands Oncology Group (22)</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>479-872-8130</phone>
    </contact>
    <investigator>
      <last_name>Joseph T. Beck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PCR Oncology</name>
      <address>
        <city>Pismo Beach</city>
        <state>California</state>
        <zip>93449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>805-474-9143</phone>
    </contact>
    <investigator>
      <last_name>David Palchak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists Florida Cancer Specialists (31</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-366-4100</phone>
    </contact>
    <investigator>
      <last_name>Daniel L. Spitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>904-538-3667</phone>
    </contact>
    <investigator>
      <last_name>Daniele Montgomery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ocala Oncology Center Dept. of Ocala Oncology Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thomas Cartwright</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute Memorial Healthcare System</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>954-844-6868</phone>
    </contact>
    <investigator>
      <last_name>Luis E. Raez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center, LLC</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>706-353-2990</phone>
    </contact>
    <investigator>
      <last_name>Petros Nikolinakos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeastern Regional Medical Center</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>770-400-6000</phone>
    </contact>
    <investigator>
      <last_name>Navneet Dhillon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Developmental Therapeutics Ins</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>312-695-0184</phone>
    </contact>
    <investigator>
      <last_name>Melissa Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Care IL. Cancer Care</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615-7828</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>847-827-9060</phone>
    </contact>
    <investigator>
      <last_name>Leonard Klein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America Southwestern Regional Med. Ctr</name>
      <address>
        <city>Schaumburg</city>
        <state>Illinois</state>
        <zip>60173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>918-286-5435</phone>
    </contact>
    <investigator>
      <last_name>Michael Kayser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Indiana Univ. - Purdue Univ.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>317-278-8845</phone>
    </contact>
    <investigator>
      <last_name>Bert O'Neil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics Regulatory Contact 2</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>319-353-8775</phone>
    </contact>
    <investigator>
      <last_name>Daniel Vaena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associates in Oncology/Hematology, P.C. Assoc. in Oncology/Hematology</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paul M. Thambi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro MN CCOP - Coon Rapids</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>763-712-2176</phone>
    </contact>
    <investigator>
      <last_name>Noel Laudi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada CCC of Nevada (21)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>903-579-9800</phone>
    </contact>
    <investigator>
      <last_name>Fadi Braiteh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C. NYOH Latham</name>
      <address>
        <city>Troy</city>
        <state>New York</state>
        <zip>12180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>518-786-3122</phone>
    </contact>
    <investigator>
      <last_name>Charles Weissman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Chapel Hill Physician Office Building</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>919-843-5497</phone>
    </contact>
    <investigator>
      <last_name>Juneko Grilley-Olson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cleveland Clinic (19)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>216-444-8258</phone>
    </contact>
    <investigator>
      <last_name>Davendra Sohal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Clinical Studies Cancer Institute &amp;Research Ctr</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>541-741-3451</phone>
    </contact>
    <investigator>
      <last_name>Jeff Sharman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists Compass Oncology (35)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists Vancouver Cancer Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>360-449-6522</phone>
    </contact>
    <investigator>
      <last_name>Christopher A Yasenchak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Oregon Health 7 Science U (56)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>503-494-8534</phone>
    </contact>
    <investigator>
      <last_name>Matthew Taylor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital and Health Network St Luke's (2)</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>484-503-4150</phone>
    </contact>
    <investigator>
      <last_name>Sanjiv S. Agarwala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abington Hematology Oncology Associates, Inc Abington Hem Onc Assoc (5)</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>215-706-2034</phone>
    </contact>
    <investigator>
      <last_name>Marc J Chernoff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours St. Francis Hospital Bon Secours</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>864-255-1517</phone>
    </contact>
    <investigator>
      <last_name>Howland Crosswell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The West Clinic Dept. of the West Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>901-683-0055</phone>
    </contact>
    <investigator>
      <last_name>Lee S. Schwartzberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute Sarah Cannon Research Inst (51</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>615-279-0464</phone>
    </contact>
    <investigator>
      <last_name>Kent C. Shih</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sammons Cancer Center - Texas Oncology Sammons Cancer Center (10)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>78246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>C Lance Cowey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. Presbyterian Hospital (3)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>214-265-2080</phone>
    </contact>
    <investigator>
      <last_name>Kristi J. McIntyre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. Texas Oncology - Midland</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>432-687-1949</phone>
    </contact>
    <investigator>
      <last_name>David L. Watkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants Oncology Group</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>832-824-5383</phone>
    </contact>
    <investigator>
      <last_name>Julio Peguero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>713-745-0147</phone>
    </contact>
    <investigator>
      <last_name>Sarina Piha-Paul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas / HOAST CCC of So. TX-San Antonio (3)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>210-424-2620</phone>
    </contact>
    <investigator>
      <last_name>Sharon T. Wilks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center Dept.ofTylerCancerCtr. (2)</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Donald A. Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center Intermountain Healthcare</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>435-688-4900</phone>
    </contact>
    <investigator>
      <last_name>Lincoln Nadauld</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alexander Spira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties NW Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>253-841-4296</phone>
    </contact>
    <investigator>
      <last_name>Sibel Blau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.signaturetrial.com</url>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 2, 2014</lastchanged_date>
  <firstreceived_date>June 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RAS, RAF, MEK, NF1, MEK162, signature, papillary thyroid, small intestine, bladder, esophagus, lung cancer, NSCLC, acute myelogenous leukemia, AML</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
